Document is current

Article History

Received: 27 April 2022

Accepted: 19 August 2022

First Online: 7 September 2022

Declarations

:

: The study was conducted following the ethical principles of the Declaration of Helsinki and as per local regulations, including privacy laws. Data were provided anonymized and may be used for research purposes without the approval of an ethics committee or informed consent. In addition, the protocol of the BARI study was validated by a panel of clinical experts, classified by the Agency of Medicines and Medical Devices (AEMPS) as an observational study, and approved by the Ethics Committee of Hospital Clinic de Barcelona (HCB/2020/1132), which waived the need for participant consent.

: NA.

: CG, MM, HB, and CDC are Sanofi employees. MC, HL, and GB are IQVIA employees. FF, JCDS, CR, JFR, and CRC have received fees from Sanofi. JCDS reports Advisory Board from Boehringer Ingelheim; personal fees and Advisory Board from GSK; grants, personal fees, and Advisory Board from AstraZeneca; personal fees and Advisory Board from Bial; non-financial support from Mundipharma; personal fees from Sanofi; Advisory Board from Novartis, outside the submitted work. FF reports Advisory Board and personal fees from Sanofi, Pfizer, MSD, Gilead and personal fees or non-financial support from Bial, AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Tecnifar, Lilly, Bayer, and Roche outside the submitted work.